Results of the phase I/II MonumenTAL-1 trial of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma were presented at the 2022 ASH Annual Meeting and Exposition (Abstract 157).
Question 1 of 5
All patients enrolled in the MonumenTAL-1 trial had received a minimum of ___ prior lines of therapy.
